Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS

Affiliations

Comment

Jeanne M Schilder et al. Front Pharmacol. 2023.

. 2023 Aug 16:14:1241524.

doi: 10.3389/fphar.2023.1241524. eCollection 2023.

No abstract available

Keywords: FAERS; PARP inhibitors; lymphangioleiomyomatosis; niraparib; pharmacovigilance.

Conflict of interest statement

JS, AG, TB, GY, and JK are employees of GSK.

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X, Chen L, Gai D, He S, Jiang X, Zhang N. Tian X, et al. Front Pharmacol. 2022 Mar 25;13:851246. doi: 10.3389/fphar.2022.851246. eCollection 2022. Front Pharmacol. 2022. PMID: 35401230 Free PMC article.

1. Almenoff J., Tonning J. M., Gould A. L., Szarfman A., Hauben M., Ouellet-Hellstrom R., et al. (2005). Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 28 (11), 981–1007. 10.2165/00002018-200528110-00002 - DOI - PubMed
1. Bate A., Evans S. J. (2009). Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 18 (6), 427–436. 10.1002/pds.1742 - DOI - PubMed
1. DuMouchel W. (1999). Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53 (3), 177–190. 10.1080/00031305.1999.10474456 - DOI
1. Guo M., Shu Y., Chen G., Li J., Li F. (2022). A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci. Rep. 12 (1), 20601. 10.1038/s41598-022-23726-4 - DOI - PMC - PubMed
1. Harknett E. C., Chang W. Y., Byrnes S., Johnson J., Lazor R., Cohen M. M., et al. (2011). Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 104 (11), 971–979. 10.1093/qjmed/hcr116 - DOI - PubMed